Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

被引:0
|
作者
Waede, Mie [1 ,2 ,3 ]
Voss, Lasse F. [4 ]
Kingo, Christina [1 ,2 ,3 ]
Moeller, Jesper B. [3 ,5 ]
Elkjaer, Maria L. [1 ,2 ,3 ,6 ]
Illes, Zsolt [1 ,2 ,3 ,7 ]
机构
[1] Odense Univ Hosp, Dept Neurol, Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Univ Southern Denmark, Dept Mol Med, Odense, Denmark
[4] Tech Univ Denmark, Dept Hlth Technol, Sect Expt & Translat Immunol, Lyngby, Denmark
[5] Univ Southern Denmark, Danish Inst Adv Study, Odense, Denmark
[6] Univ Hamburg, Inst Computat Syst Biol, Hamburg, Germany
[7] Univ Southern Denmark, BRIDGE Brain Res Interdisciplinary Guided Excellen, Odense, Denmark
来源
关键词
NATURAL-KILLER-CELLS; T-CELLS; CHEMOKINE RECEPTORS; NK CELLS; CEREBROSPINAL-FLUID; ACTIVATION; EXPRESSION; RITUXIMAB; CD38; INFLAMMATION;
D O I
10.1002/acn3.52182
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Anti-CD20 therapy is a highly effective treatment for multiple scle-rosis (MS). In this study, we investigated MS-related changes in peripheralblood mononuclear cell (PBMC) subsets compared to healthy controls and lon-gitudinal changes related to the treatment.Methods: Multicolor spectral flowcytometry analysis was performed on 78 samples to characterize disease- andtreatment-related PBMC clusters. Blood samples from MS patients were col-lected at baseline and up to 8 months post-treatment, with three collectionpoints after treatment initiation. Unsupervised clustering tools and manual gat-ing were applied to identify subclusters of interest and quantify changes. Results: B cells were depleted from the periphery after anti-CD20 treatment asexpected, and we observed an isolated acute, transitory drop in the proportionof natural killer (NK) and NKT cells among the main populations of PBMC(P=0.03,P=0.004). Major affected PBMC subpopulations were cytotoxicimmune cells (NK, NKT, and CD8(+)T cells), and we observed a higher propor-tion of cytotoxic cells with reduced brain-homing ability and a higher regula-tory function as a long-term anti-CD20-related effect. Additionally, anti-CD20therapy altered distributions of memory CD8(+)T cells and reduced exhaustionmarkers in both CD4(+)and CD8(+)T cells.Interpretation: The findings of thisstudy elucidate phenotypic clusters of NK and CD8(+)T cells, which have previ-ously been underexplored in the context of anti-CD20 therapy. Phenotypicmodifications towards a more regulatory and controlled phenotype suggest thatthese subpopulations may play a critical and previously unrecognized role inmediating the therapeutic efficacy of anti-CD20 treatments.
引用
收藏
页码:2657 / 2672
页数:16
相关论文
共 50 条
  • [21] Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
    Bazzi, Sam A.
    Maguire, Cole
    Holay, Nisha
    Geltman, Janelle
    Hurley, Kerin
    DiPasquale, Chris
    Abigania, Melissa
    Olson, Eric
    Ehrlich, Lauren I. R.
    Triplett, Todd A.
    Melamed, Esther
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [22] Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles
    Fong, Chloe C. C.
    Spencer, Julian
    Howlett-Prieto, Quentin
    Feng, Xuan
    Reder, Anthony T.
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [23] Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO
    van Kempen, Zoe L. E.
    Hogenboom, Laura
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 693 - 695
  • [24] Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients
    Elgenidy, Anas
    Abdelhalim, Nagham Nader
    Al-kurdi, Mohammed Al-mahdi
    Mohamed, Lobna A.
    Ghoneim, Mohamed M.
    Fathy, Ahmed Wagdy
    Hassaan, Hazem Khaled
    Anan, Ahmed
    Alomari, Omar
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [25] Anti-CD20 therapy for multiple sclerosis-associated uveitis: A case series
    Stascheit, Frauke
    Ruebsam, Anne
    Otto, Carolin
    Meisel, Andreas
    Ruprecht, Klemens
    Pleyer, Uwe
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (10) : 3028 - 3038
  • [26] Unraveling the T-B tangle in anti-CD20 multiple sclerosis therapy
    Waisman, Ari
    Ebering, Anna
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (51) : 25376 - 25377
  • [27] Follow-up of a French cohort of progressive multiple sclerosis patients treated with anti-CD20 antibodies
    Einsiedler, M.
    Kremer, L.
    Fleury, M.
    Collongues, N.
    De Seze, J.
    Bigaut, K.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 211 - 211
  • [28] Ublituximab: a new anti-CD20 agent for multiple sclerosis
    Oh, Jiwon
    Bar-Or, Amit
    LANCET NEUROLOGY, 2022, 21 (12): : 1070 - 1072
  • [29] A personalized approach for anti-CD20 therapies in multiple sclerosis
    Hogenboom, Laura
    Kempen, Zoe L. E. van
    Kalincik, Tomas
    Bar-Or, Amit
    Killestein, Joep
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [30] Repeated iv anti-CD20 treatment in multiple sclerosis: Long-term effects on peripheral immune cell subsets
    Feige, Julia
    Moser, Tobias
    Akguen, Katja
    Schwenker, Kerstin
    Hitzl, Wolfgang
    Haschke-Becher, Elisabeth
    Ziemssen, Tjalf
    Sellner, Johann
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (02): : 450 - 465